Synopsis
Synopsis
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Acid, Phenylethylbarbituric
2. Gardenal
3. Hysteps
4. Luminal
5. Monosodium Salt Phenobarbital
6. Phenemal
7. Phenobarbital
8. Phenobarbital, Monosodium Salt
9. Phenobarbitone
10. Phenylbarbital
11. Phenylethylbarbituric Acid
12. Sodium, Phenobarbital
1. 57-30-7
2. Phenobarbital Sodium Salt
3. Sodium Phenobarbital
4. Sodium Phenobarbitone
5. Luminal Sodium
6. Sodium Luminal
7. Sodium Phenobarbiturate
8. Phenobarbital Sodique
9. Sodium Phenylethylbarbiturate
10. Sodium Phenylethylmalonylurea
11. Sodium 5-ethyl-5-phenylbarbiturate
12. Phenobarbital, Sodium
13. Phenobarbitalum Natricum
14. Sodium 5-ethyl-4,6-dioxo-5-phenyl-1,4,5,6-tetrahydropyrimidin-2-olate
15. 5-ethyl-5-phenylbarbituric Acid Sodium Salt
16. Phenyl-aethyl-barbitursaeure Natrium
17. Sodium 5-ethyl-4,6-dioxo-5-phenyl-1h-pyrimidin-2-olate
18. Phenobarbitone Sodium
19. Phenemalnatrium
20. Phenobal Sodium
21. Phenobarbital Na
22. Sol Phenobarbital
23. Sol Phenobarbitone
24. Phenobarbitalnatrium
25. Phenobarbital Elixir
26. Phenobarbiton-natrium
27. Soluble Phenobarbital
28. Soluble Phenobarbitone
29. 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl-, Monosodium Salt
30. Sodium;5-ethyl-4,6-dioxo-5-phenyl-1h-pyrimidin-2-olate
31. Sw9m9bb5k3
32. Phenobarbitone Sodium Salt
33. Chebi:8070
34. Fenobarbital Sodico
35. Fenobarbital Natrium
36. Ccris 503
37. Fenobarbital Natrium [polish]
38. Fenobarbital Sodico [inn-spanish]
39. Phenobarbital Sodique [inn-french]
40. Einecs 200-322-3
41. Phenobarbitalum Natricum [inn-latin]
42. Unii-sw9m9bb5k3
43. Phenylethylbarbituric Acid, Sodium Salt
44. Phenyl-aethyl-barbitursaeure Natrium [german]
45. Phenobarbital Sodium [usp:inn:jan]
46. Luminal Sodium (tn)
47. 5-ethyl-5-phenyl-2,4,6-(1h,3h,5h)pyrimidinetrione Monosodium Salt
48. Dsstox_cid_1123
49. Dsstox_rid_75954
50. Barbituric Acid, 5-ethyl-5-phenyl-, Sodium Salt
51. Dsstox_gsid_21123
52. Schembl42037
53. Dtxsid0021123
54. Tox21_300271
55. Phenobarbital Sodium (jan/usp/inn)
56. Akos015960550
57. Cas-57-30-7
58. Ncgc00253999-01
59. Ac-11674
60. Db-053032
61. P0890
62. D00701
63. A831383
64. W-105476
65. Q26840934
66. Sodium;5-ethyl-5-phenylpyrimidin-3-ide-2,4,6-trione
67. 5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione Sodium Salt
68. Sodium 5-ethyl-4,6-bis(oxidanylidene)-5-phenyl-1h-pyrimidin-2-olate
Molecular Weight | 254.22 g/mol |
---|---|
Molecular Formula | C12H11N2NaO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
Exact Mass | 254.06673650 g/mol |
Monoisotopic Mass | 254.06673650 g/mol |
Topological Polar Surface Area | 81.6 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 378 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Cytochrome P-450 CYP2B6 Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inducers.)
Cytochrome P-450 CYP3A Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inducers.)
Excitatory Amino Acid Antagonists
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
99
PharmaCompass offers a list of Phenobarbital Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Phenobarbital Sodium manufacturer or Phenobarbital Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Phenobarbital Sodium manufacturer or Phenobarbital Sodium supplier.
PharmaCompass also assists you with knowing the Phenobarbital Sodium API Price utilized in the formulation of products. Phenobarbital Sodium API Price is not always fixed or binding as the Phenobarbital Sodium Price is obtained through a variety of data sources. The Phenobarbital Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 8050-96-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 8050-96-2, including repackagers and relabelers. The FDA regulates 8050-96-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 8050-96-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 8050-96-2 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 8050-96-2 supplier is an individual or a company that provides 8050-96-2 active pharmaceutical ingredient (API) or 8050-96-2 finished formulations upon request. The 8050-96-2 suppliers may include 8050-96-2 API manufacturers, exporters, distributors and traders.
click here to find a list of 8050-96-2 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 8050-96-2 DMF (Drug Master File) is a document detailing the whole manufacturing process of 8050-96-2 active pharmaceutical ingredient (API) in detail. Different forms of 8050-96-2 DMFs exist exist since differing nations have different regulations, such as 8050-96-2 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 8050-96-2 DMF submitted to regulatory agencies in the US is known as a USDMF. 8050-96-2 USDMF includes data on 8050-96-2's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 8050-96-2 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 8050-96-2 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 8050-96-2 Drug Master File in Japan (8050-96-2 JDMF) empowers 8050-96-2 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 8050-96-2 JDMF during the approval evaluation for pharmaceutical products. At the time of 8050-96-2 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 8050-96-2 suppliers with JDMF on PharmaCompass.
A 8050-96-2 CEP of the European Pharmacopoeia monograph is often referred to as a 8050-96-2 Certificate of Suitability (COS). The purpose of a 8050-96-2 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 8050-96-2 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 8050-96-2 to their clients by showing that a 8050-96-2 CEP has been issued for it. The manufacturer submits a 8050-96-2 CEP (COS) as part of the market authorization procedure, and it takes on the role of a 8050-96-2 CEP holder for the record. Additionally, the data presented in the 8050-96-2 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 8050-96-2 DMF.
A 8050-96-2 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 8050-96-2 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 8050-96-2 suppliers with CEP (COS) on PharmaCompass.
A 8050-96-2 written confirmation (8050-96-2 WC) is an official document issued by a regulatory agency to a 8050-96-2 manufacturer, verifying that the manufacturing facility of a 8050-96-2 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 8050-96-2 APIs or 8050-96-2 finished pharmaceutical products to another nation, regulatory agencies frequently require a 8050-96-2 WC (written confirmation) as part of the regulatory process.
click here to find a list of 8050-96-2 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 8050-96-2 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 8050-96-2 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 8050-96-2 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 8050-96-2 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 8050-96-2 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 8050-96-2 suppliers with NDC on PharmaCompass.
8050-96-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 8050-96-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 8050-96-2 GMP manufacturer or 8050-96-2 GMP API supplier for your needs.
A 8050-96-2 CoA (Certificate of Analysis) is a formal document that attests to 8050-96-2's compliance with 8050-96-2 specifications and serves as a tool for batch-level quality control.
8050-96-2 CoA mostly includes findings from lab analyses of a specific batch. For each 8050-96-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
8050-96-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (8050-96-2 EP), 8050-96-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (8050-96-2 USP).